Subtle onset or changes in symptoms of ATTR-CM can indicate worsening heart failure. Learn how to track symptoms and when to seek medical attention.

Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival. Long-term ATTR-CM trial data show durable benefits ...

Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis. The FDA has lifted a hold on one of ...

The same abnormal proteins that can build up in your heart when you have transthyretin cardiac amyloidosis (ATTR-CM) can also leave deposits in your spine, resulting in spinal stenosis. Spinal ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition that makes the heart stiff and less flexible, making it harder for the heart to pump. ATTR-CM doesn't always cause symptoms. When it does, ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...

ATTR-CM can be a life-changing diagnosis, and if you’re an older adult, it can have an especially large impact on your quality of life. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a rare but ...

Heart failure can be a scary diagnosis. But what if there’s something else going on that’s even harder to spot? Meet transthyretin cardiac amyloidosis (ATTR-CM)—a serious heart condition that is ...

A promising new way to diagnose transthyretin amyloid cardiomyopathy (ATTR-CM or -CA) has the field waiting in anticipation. Early-phase research suggests that the positron emission tomography ...

The last time I spoke about Intellia Therapeutics (NTLA), it was with a Seeking Alpha article entitled "Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication" With respect to this ...